Modern Resin Hemoadsorption Shows Promise for Severe Poisonings, Including Calcium Channel Blockers and Organophosphates

In 2012 the World Health Organization estimated that more than 800,000 people died by suicide, and poisoning was a major part of that toll. Three-quarters of those deaths occurred in low- and middle-income countries, and an estimated 30% involved pesticides. In India, organophosphates make up at least 40% of pesticides. A new review of blood purification evidence asks whether a modern form of filtering poison from the blood can help the sickest of these patients.

The idea is old. In 1914 Abel showed that a dialyser could remove salicylate from dogs, and by 1946 dialysis was being used clinically. Resin hemoperfusion for barbiturates was described in 1958. In 1965 Dunea introduced charcoal hemoperfusion, noting that it adsorbed drugs but also caused nausea, hypotension and thrombocytopenia. In 1976 Amberlite XAD-4 resin was used for lipid-bound drugs and removed them substantially, the first clinical use of styrene divinylbenzene copolymers. By the 1990s a study of about 800 patients put numbers on the harms: hypotension in 22%, bleeding in 3%, thrombocytopenia in 31%, and mortality above 44%. Skepticism through the 1980s and 1990s was understandable. Since then the materials have moved from uncoated activated carbon to encapsulated carbon and now to synthetic porous polymer beads built for blood compatibility, mechanical strength and thermal stability.

Whether a poison can be pulled from the blood depends on its molecular weight, protein binding, volume of distribution, solubility and the body's own clearance. Small molecules under 500 daltons cross membranes easily, and synthetic resins can have pores admitting molecules up to 60,000 daltons. Drugs bound to protein cannot pass filters, though binding to albumin saturates as concentrations rise, which makes removal possible. Lipid-soluble drugs with low protein binding spread widely through tissue, with a volume of distribution above 1 L/kg, and are hard to reach. Extracorporeal clearance is worthwhile if it raises endogenous clearance by 30%, or if the body's own clearance is below 4 mL/kg/min.

The Extracorporeal Treatment in Poisoning Workgroup, EXTRIP, has reviewed more than 20 drugs and toxins. It recommends hemoadsorption for acetaminophen, barbiturates, carbamazepine, phenytoin, salicylates, thallium, theophylline and valproic acid. It does not recommend it for calcium channel blockers or digoxin. Charcoal hemoadsorption for diltiazem overdose showed no improvement, and diltiazem and amlodipine are both protein-bound, lipophilic and widely distributed in tissue.

The review argues modern resin cartridges may change that. The polymers adsorb lipophilic substances through van der Waals forces. In an ex vivo model, almost 90% of amlodipine was removed within two hours. A case report using the Jafron HA 230 cartridge reversed shock in less than one elimination half-life, using two six-hour cycles 18 hours apart. Repeating cycles lets toxin move from tissue back into the blood to be captured. A retrospective study of 24 patients with calcium channel blocker poisoning and shock compared hemoadsorption (13 patients) with standard care (11). The hemoadsorption group was sicker at the start, yet its mean arterial pressure improved more over the first 48 hours, lactate fell faster (14 hours versus 4), high-dose insulin therapy tended to be shorter, and only one patient died (7.7%).

For organophosphates, a 2022 meta-analysis pooled 11 Chinese studies covering 811 patients with acute severe poisoning. Hemoperfusion plus hemofiltration was associated with lower mortality (odds ratio 0.38, 95% CI 0.25–0.57), less atropine, shorter mechanical ventilation and faster restoration of cholinesterase, though methodological quality was poor. A randomized trial in South Africa enrolled 40 patients on invasive ventilation and gave two six-hour Jafron HA 230 cycles 12 to 18 hours apart. Median ICU stay fell from 17 days to 10, atropine use and ventilation time dropped, and costs fell by more than €7,000 per patient. Severe complications, including death, were significantly lower, with no significant effect on platelets, bleeding or transfusion. A recent observational study of 75 patients also found fewer severe complications with hemoadsorption despite greater illness severity.

The review proposes a care pathway: assess severity and the poison's physicochemical suitability, weigh risks such as vascular access, anticoagulation, infection and low platelets, ensure an appropriate setting, run cycles of 6 to 12 hours, and stop when the patient and biomarkers recover, for example a cholinesterase rise above 40%.

The limits are real. Only one randomized trial followed CONSORT reporting; the others lacked randomization, concealment or blinding. Toxins and cartridges vary, observational studies invite bias, and most were single-centre with small samples. The authors conclude that multicycle modern resin hemoadsorption has improved outcomes in both calcium channel blocker and organophosphate poisoning. Larger, rigorous trials will be needed before the pathway can be called standard care.